Skip to content
Clinical Trials – home

University General Hospital of Patras

Verified siteinfo

Greece Rio, 26504 Achaia Patras, Greece

  • 1 trial recruiting
  • Idiopathic pulmonary fibrosis · Pulmonary sarcoidosis
  • Adult patients

About Specializations

University General Hospital of Patras in Patras, Greece specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Pulmonary sarcoidosis, and other specialisations. This site conducts important research.

Main research areas of the site

Active Pulmonary Sarcoidosis

The Respiratory Medicine department at University General Hospital of Patras is conducting a trial aimed at reducing granulomatous inflammation using a novel agent, evaluated through advanced imaging.

  • Evaluation of anti‑inflammatory therapy
  • Use of [18F]FDG PET/CT imaging to monitor lung lesions
  • Assessment of safety and efficacy in a 12‑week regimen

This research seeks to improve treatment options for patients with active pulmonary sarcoidosis by targeting disease activity directly.

Idiopathic Pulmonary Fibrosis

A comparative study at the same site examines a new antifibrotic compound against the standard therapy to slow lung function decline in idiopathic pulmonary fibrosis.

  • Head‑to‑head efficacy comparison
  • Focus on preserving forced vital capacity
  • Monitoring safety profile over the study period

The goal is to identify a more effective treatment for this progressive respiratory tract disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Rio26504 Achaia PatrasGreece
Recruiting now
1 trial
Conditions studied
2
Partner status
Verified site

More sites in PatrasGreece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methylmorpholino)Piperidin-1-Yl)-1H- 1,2,4-Triazol-3-Amine
  • Sponsor:Molecure S.A.

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.